Upgrade Alert for Exact Sciences (EXAS)
Exact Sciences (NASDAQ:EXAS) was upgraded from Hold to Buy at Craig-Hallum today. The stock closed yesterday at $11.25 on volume of 36.6 million shares, above average daily volume of 1.9 million.
EXACT Sciences Corporation is an applied genomics company that develops and commercializes proprietary DNA-based tests for the early detection of cancer. The Company's PreGen-Plus is intended for the early detection of colorectal cancer in the average-risk population.
In the past 52 weeks, Exact Sciences share prices have been bracketed by a low of $4.67 and a high of $32.85 and closed yesterday at $11.25, 141% above that low price. Over the past week, the 200-day moving average (MA) has gone down 3.6% while the 50-day MA has remained constant.
There is potential upside of 11.1% for shares of Exact Sciences based on a current price of $11.25 and an average consensus analyst price target of $12.50. The stock should discover initial support at its 200-day moving average (MA) of $11.23 and subsequent support at its 50-day MA of $6.61.
SmarTrend is monitoring the recent change of momentum in Exact Sciences. Please refer to our Company Overview for the results of our proprietary technical indicators that have been scanning shares of Exact Sciences in search of a potential trend change.
Keywords: analyst upgrades/downgrades exact sciences